Side-by-side · Research reference

Follistatin-344vsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED4/58 cited

BFDA-ApprovedFlagship14/45 cited

Follistatin-344

Myostatin/Activin Antagonist · Research Use

15–25%FST/MSTN ratio ↑

344 AACirculating isoform

ResearchPhase status

Research · No approved protocol

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Follistatin-344

Tirzepatide

Primary target

Myostatin (MSTN/GDF-8) and Activin A

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

FST-344 binds MSTN/Activin → prevents ActRIIB receptor engagement → disinhibits muscle anabolism

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Elevated follistatin/myostatin ratio, increased muscle protein synthesis, attenuated muscle atrophy signalingJeong 2026

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

Yes — indirect antagonist, preserves endogenous regulation

Glucose-dependent insulin release preserves physiological feedback

Origin

Endogenous glycoprotein, 344-AA isoform lacking heparin-binding domain (vs FST-315)

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

Not documented in available trials (endogenous protein)

—

02Dosage Protocols

Parameter

Follistatin-344

Tirzepatide

Clinical protocol

None — no approved dosing regimen

Follistatin-344 measured as endogenous biomarker, not administered exogenously in cited trials.

—

Research context

Endogenous modulation via exercise + nutrition

Resistance training + EAA intake elevated FST/MSTN ratio by 15–25% in 12-week RCT (older women).

—

Evidence basis

Human observational / biomarker studies

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Half-life

Not established

Circulating isoform; lacks tissue-binding domain of FST-315.

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

Duration

—

Indefinite for chronic indication

Reconstitution

—

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

—

Once weekly, any time of day

03Metabolic / Fat Loss Evidence

Parameter

Follistatin-344

Tirzepatide

Primary target

Muscle mass preservation, not direct lipolysis

—

Indirect fat effect

Increased lean mass → elevated resting metabolic rate

Not primary mechanism. Muscle-sparing during deficit.

—

Clinical evidence

Lorcaserin trial (6 mo) showed no MAFI axis changes during fat lossRamirez-Cisneros 2026

Suggests follistatin not primary driver of fat loss in weight-reduction interventions.

—

GLP-1RA studies

Liraglutide (35 days) — no significant MAFI axis modulation despite fat/lean changes

—

04Side Effects & Safety

Parameter

Follistatin-344

Tirzepatide

Clinical safety data

None — no human exogenous administration trials in literature

—

Theoretical risks

Excessive myostatin inhibition → muscle overgrowth, impaired glucose tolerance

Based on myostatin-null animal models and clinical myostatin inhibitor trials.

—

Endogenous elevation (exercise)

No adverse effects reported in 12-week resistance + EAA trials

—

Cancer risk (theoretical)

Myostatin inhibition may promote tumor growth in malignancy (preclinical data)

—

Regulatory status

Not approved for human use — research peptide only

—

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

Contraindicated

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Follistatin-344

·Active malignancy
·No approved protocol — research use only

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Follistatin-344

·Insulin resistance / Type 2 diabetes (monitor glucose)
·Pregnancy / lactation (unknown safety profile)

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Follistatin-344

Tirzepatide

1. Regulatory status

Follistatin-344 is not approved for human administration. All cited studies measure endogenous serum follistatin as a biomarker, not as an exogenous therapeutic agent.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Endogenous modulation

Resistance exercise combined with essential amino acid (EAA) supplementation elevated the follistatin/myostatin ratio by 15–25% in 12-week randomized trials. Protein intake (1.2–1.5 g/kg/day) synergizes with training to upregulate endogenous follistatin.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Measurement context

Serum follistatin and follistatin/myostatin ratio are used diagnostically in sarcopenia screening and as biomarkers of muscle anabolic balance in clinical trials.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Research consideration

Gene therapy and recombinant follistatin delivery are under preclinical investigation for muscular dystrophy and sarcopenia. No human safety or efficacy data for exogenous FST-344 administration.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

—

Pen-supplied. Research vial: 27–31G insulin syringe.

06Stack Synergy

Follistatin-344

+ BPC-157

Multi-pathway

View BPC-157 →

Follistatin-344 (myostatin antagonist) and BPC-157 (tissue repair peptide) address complementary pathways in muscle recovery. FST-344 promotes muscle protein synthesis by disinhibiting myostatin signaling, while BPC-157 accelerates healing of tendons, ligaments, and microtears via angiogenesis and collagen synthesis. Combined, they may support both hypertrophy and structural repair during high-volume training or injury recovery.

Follistatin-344: No approved protocol — endogenous modulation via resistance exercise + EAA
BPC-157: 250–500 mcg SQ · twice daily · near injury site or systemic
Duration: 4–8 weeks
Primary benefit: Muscle hypertrophy + accelerated soft tissue repair

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and anti-inflammatory signaling in muscle and connective tissue. Follistatin-344's anabolic signaling may synergize with TB-500's regenerative effects during muscle damage or overtraining, particularly in older adults where both myostatin inhibition and tissue repair are rate-limiting.

Follistatin-344: Endogenous upregulation (resistance training + protein)
TB-500: 2–5 mg SQ · twice weekly · loading phase 4 weeks, then maintenance
Frequency: Twice weekly TB-500, daily training stimulus for FST
Primary benefit: Enhanced recovery, reduced inflammation, muscle growth support

Tirzepatide

— no documented stacks